Dublin: SynOx Therapeutics makes senior appointments ahead of trial plans

SynOx Therapeutics, a late-stage clinical biopharmaceutical company developing emactuzumab, a monoclonal antibody directed against CSF-1R, for the treatment of Tenosynovial Giant Cell Tumours (TGCT), has appointed Professor Ton Logtenberg as chairman and Ray Barlow as CEO ahead of plans for a registrational trial in the USA and EU. These appointments were quickly followed by the…

You must be a HMI Subscriber to view this content.

Subscribe Now »